Nek7 Double Nickase Plasmid (h): sc-405218-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Nek7 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Nek7 Double Nickase Plasmid (h) and Nek7 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting NEK7. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Nek7 Antibody (B-5): sc-393539
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Nek7 Double Nickase Plasmid (h) | sc-405218-NIC | 20 µg | $410.00 | |||
Nek7 Double Nickase Plasmid (h2) | sc-405218-NIC-2 | 20 µg | $410.00 |
NEK7 encodes the serine/threonine kinase Nek7, a NIMA-related kinase that regulates centrosome function, mitotic spindle assembly, and progression through mitosis by coordinating microtubule dynamics and cell-cycle checkpoints. Nek7 also participates in stress-responsive signaling, including regulation of NLRP3 inflammasome activation and downstream inflammatory outputs, linking cell-division control to innate immune pathways. Dysregulated NEK7 activity or expression has been associated with aberrant proliferation and genomic instability, making it relevant to studies of tumor biology and cell-cycle–driven pathologies. As a result, NEK7 is frequently investigated in models of mitotic regulation, cytoskeletal remodeling, and inflammation-associated cellular phenotypes.
Nek7 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the NEK7 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within NEK7. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt NEK7 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of NEK7-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.